The Evening versus Morning Polypill Utilization Study: the TEMPUS rationale and design

Abstract

Background and rationale

In clinical practice, blood pressure (BP)-lowering agents are generally prescribed for use in the morning, whereas (short-acting) statins are recommended for use in the evening. There is evidence that the reduction in LDL cholesterol (LDL-c) achieved with short-acting statins is superior when taken in the evening and reported improvement in BP control when aspirin and BP-lowering agents are taken in the evening. However, it is unclear whether the additional reduction in LDL-c and BP is offset by a reduction in adherence, given that taking medication in the evening may be less typical or convenient. There is therefore uncertainty concerning the best timing of administration of a cardiovascular combination pill such as the polypill.

Aim

The aim of TEMPUS (NCT01506505), a prospective randomized open blinded endpoint (PROBE) crossover trial, is to evaluate whether there is a difference in LDL-c levels or 24-hour ambulatory BP in individuals at increased risk of cardiovascular disease when the cardiovascular polypill is taken in the evening compared to the morning. An additional aim is to assess the effect of the polypill on LDL-c and BP compared to the administration of separate pills of identically dosed components of the polypill.

Methods

In total 75 participants with established cardiovascular disease or an intermediate to high risk for cardiovascular disease are randomly allocated to the sequence of three different treatments of 6–8 weeks: (1) the cardiovascular polypill (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, and hydrochlorothiazide 12.5 mg) in the evening; (2) the polypill in the morning; and (3) the use of the identically dosed agents in separate pills taken at different time points during the day. The primary endpoint is the difference in LDL-c and mean 24-hour ambulatory systolic BP. Secondary outcomes are the difference in relative risk reduction, biochemistry, platelet function and pulse wave analysis, participants’ adherence, and acceptability.

Conclusions

TEMPUS will evaluate the effect of timing of the administration of a cardiovascular polypill on LDL-c and BP measurements in patients with an intermediate or high risk for cardiovascular disease.

Keywords

Antiplatelet agents blood pressure-lowering agents cardiovascular disease cholesterol-lowering agents chronotherapy combination therapy polypill prevention

Get full access to this article

View all access options for this article.

References

Callow

. Cardiovascular disease 2005 – the global picture. Vascul Pharmacol 2006; 45: 302–307.

Rayner

Allender

Scarborough

. Cardiovascular disease in Europe. Eur J Cardiovasc Prev Rehabil 2009; 16. Suppl 2. S43–S47.

Group

. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041.

Collaboration

. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.

Group

HPSC

. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.

Yusuf

Sleight

Pogue

. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.

Lafeber M, Spiering W, Singh K, et al. The cardiovascular polypill in high-risk patients. Eur J Cardiovasc Prev Rehabil 2011.

Yusuf

Islam

Chow

. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378: 1231–1243.

Wald

Law

. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419–1419.

10.

World Health Organization. Secondary prevention of noncommuncicable diseases in low- and middle-income countries through community-based and health service interventions; report of WHO–Wellcome Trust Meeting of Experts, 1–3 August 2001 , Hixton, Cambridge, UK. Geneva: WHO, 2002.

11.

Yusuf

. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2–3.

12.

Jones

Schoeller

. Evidence for diurnal periodicity in human cholesterol synthesis. J Lipid Res 1990; 31: 667–673.

13.

Parker

McNamara

Brown

. Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Invest 1984; 74: 795–804.

14.

Saito

Yoshida

Nakaya

. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb 1991; 11: 816–826.

15.

Wallace

Chinn

Rubin

. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ 2003; 327: 788–788.

16.

Hermida

Ayala

Calvo

. Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol 2005; 46: 975–983.

17.

Snoep

Hovens

Pasha

. Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. Hypertension 2009; 54: 1136–1142.

18.

Hermida

Ayala

Mojon

. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010; 27: 1629–1651.

19.

Vrijens

Vincze

Kristanto

. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336: 1114–1117.

20.

Simons

Algra

van de Laak

. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999; 15: 773–781.

21.

Farmer

. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999; 21: 1074–1090. discussion 3.

22.

Avanzini

Palumbo

Alli

. Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP) – Hypertension study. Am J Hypertens 2000; 13: 611–616.

23.

Hermida

Ayala

Calvo

. Administration time-dependent effects of aspirin on blood pressure in untreated hypertensive patients. Hypertension 2003; 41: 1259–1267.

24.

Kriszbacher

Ajtay

Koppan

. Can the time of taking aspirin influence the frequency of cardiovascular events? Am J Cardiol 2005; 96: 608–610.

25.

Gallerani

Manfredini

Ricci

. Chronobiological aspects of acute cerebrovascular diseases. Acta Neurol Scand 1993; 87: 482–487.

26.

Mancia

Ferrari

Gregorini

. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 1983; 53: 96–104.

27.

Millar-Craig

Bishop

Raftery

. Circadian variation of blood-pressure. Lancet 1978; 1: 795–797.

28.

Morgan

Anderson

Jones

. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens 1997; 15: 205–211.

29.

Middeke M, Kluglich M and Holzgreve H. Chronopharmacology of captopril plus hydrochlorothiazide in hypertension: morning versus evening dosing. Chronobiol Int 1991; 8.

30.

Fuji

Seki

. Compliance and compliance-improving strategies in hypertension: the Japanese experience. J Hypertens 1985; 3: S19–S22.

31.

Kruse

Rampmaier

Ullrich

. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. J Clin Pharmacol Ther 1994; 32: 452–457.

32.

Kruse W, Nikolause T, Rampmaier J, et al. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharamcol 1993; 45.

33.

Mallion

Meilhac

Tremel

. Use of a microprocessor-equipped tablet box in monitoring compliance with antihypertensive treatment. J Cardiovasc Pharmacol 1992; 19: S41–S48.

34.

Mengden

Binswanger

Spuhler

. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens 1993; 11: 1403–1411.

35.

Yusuf

Pais

Afzal

. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373: 1341–1351.

36.

Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract 64: 1220–1227.

37.

Rodgers

Patel

Berwanger

. An international randomised placebo-controlled trial of a four-component combination pill (‘polypill’) in people with raised cardiovascular risk. PLoS One 2011; 6: e19857–e19857.

38.

Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol 2012 (Epub ahead of print). DOI: 10.1177/2047487312463278.